Abstract
Numerous discoveries have elucidated that long noncoding RNAs (lncRNAs) play a critical role in cancer malignant progression. However, their potential involvement in gliomas remains to be explored. Herein, the expression level of lncRNA H19 in glioma tissues, and its relevance with clinical characteristics were analyzed through Oncomine. The results showed that H19 was highly expressed in glioma tissues and its expression increased with the increase of malignancy. Next, GTEx and TCGA data were downloaded for differently expressed genes (DEGs) identification, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, and the correlation analyses between H19 expression and clinic features. Radiation therapy had a good effect on glioblastoma multiforme (GBM), but didn’t have a good effect on low grade glioma (LGG). Meanwhile, the expression level of H19 could act as an indicator molecule indicating the effect of radiotherapy. Finally, gene set enrichment analysis (GSEA) and immune infiltration analysis were conducted. It was found that H19 could affect the immune infiltration level of glioma through copy number variations, thus affecting the prognosis of glioma patients. Collectively, H19 may be involved in the occurrence and development of glioma, and has potential reference value for the relief and immunotherapy of glioma.
Highlights
Glioma is the most common primary tumor of the brain and spinal cord [1]
Since 2001, we have found eight studies involving the differential expression of H19 between glioma and normal tissues in the Oncomine database, with a total of 567 samples
There were five studies that met the screening criteria, and comprehensive analysis of the five studies showed that Median Rank=261, Pvalue =2.13E-11, indicating that H19 was highly expressed in glioma tissues and was mainly concentrated in glioblastoma multiforme (GBM) (Figure 2B, P
Summary
Glioma is the most common primary tumor of the brain and spinal cord [1]. Despite advances in surgical techniques and clinical protocols, treatment of highgrade gliomas is still a challenge, with low treatment success rate and overall survival rate. Challenges comprise of the molecular complexity of gliomas and the inconsistencies in histopathological grading, which lead to inaccurate predictions of disease progression and failure of standard treatment [2]. Because of therapeutic resistance and tumor recurrence, efforts are under way to identify the basic molecules that regulate tumor progression and to provide new approaches for individualized treatment of glioma patients [4]. Mounting evidence revealed www.aging-us.com that lncRNAs could serve as key molecules in the development and metastasis of tumors [6,7,8,9], including gliomas. LncRNA MT1JP inhibits the proliferation, invasion and migration of glioma cells by activating the PTEN/Akt signaling pathway [11]. Additional important lncRNAs correlated with gliomas need to be further explored
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
